Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms

British Journal of Surgery

Volumn 95, Issue 3, 2008, Pages 333-337

  Abisi, S ^a   Burnand, K G ^a   Humphries, J ^a   Waltham, M ^a   Taylor, P ^b   Smith, A ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLCOUMARIN 7 AMIDE; 7 AMINO 4 TRIFLUOROMETHYLCOUMARIN; AMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATHEPSIN B; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; COUMARIN DERIVATIVE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; STROMELYSIN; CATHEPSIN; CYSTATIN;

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; INCUBATION TIME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; RANK SUM TEST; SURGICAL TECHNIQUE; ABDOMINAL AORTA; ENZYMOLOGY; METABOLISM;

AGED; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CATHEPSINS; CYSTATINS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9;

EID: 40749153991     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5989     Document Type: Article

References (30)

1. Shi GP, Sukhova GK, Grabb A, Ducharme A, Rhode LH, Lee RT et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-1197.
2. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-583.
3. Sukhova GK, Wang B, Libby P, Pan JH, Zhang Y, Grubb A et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 2005; 96: 368-375.
4. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96: 318-326.
5. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 1996; 800: 157-174.
6. Gacko M, Chyczewski L, Chrostek L. Distribution, activity and concentration of cathepsin B and cystatin C in the wall of aortic aneurysm. Pol J Pathol 1999; 50: 83-86.
7. Eriksson P, Jones KG, Brown LC, Greenhalgh RM, Hamsten A, Powell JT. Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg 2004; 91: 86-89.
8. Lindholt JS, Erlandsen EJ, Henneberg EW. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001; 88: 1472-1475.
9. Dawson J, Choke E, Sayed S, Cockerill G, Loftus I, Thompson MM. Pharmacotherapy of abdominal aortic aneurysms. Curr Vasc Pharmacol 2006; 4: 129-149.
10. Rentschler M, Baxter BT. Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. Ann N Y Acad Sci 2006; 1085: 39-46.
11. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
14. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678.
15. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36: 158-163.
16. Kalyanasundaram A, Elmore JR, Manazer JR, Golden A, Franklin DP, Galt SW et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006; 43: 117-124.
17. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241: 92-101.
18. Wilson WR, Evans J, Bell PR, Thompson MM. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005; 30: 259-262.
19. Schwartz WN, Barrett AJ. Human cathepsin H. Biochem J 1980; 191: 487-497.
20. Thompson MM. Infrarenal abdominal aortic aneurysms. Curr Treat Options Cardiovasc Med 2003; 5: 137-146.
21. Kostoulas G, Lang A, Nagase H, Baici A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett 1999; 455: 286-290.
22. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453-463.
23. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31.
24. Dobrin PB, Baker WH, Gley WC. Elastolytic and collagenolytic studies of arteries. Implications for the mechanical properties of aneurysms. Arch Surg 1984; 119: 405-409.
25. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. Atherosclerosis 1987; 65: 13-21.
26. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrun M et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32:21-26.
27. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97: 279-280.
28. Lindholt JS, Erlandsen EJ, Henneberg EW. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001; 88: 1472-1475.
29. Tsujimoto A, Takemura G, Mikami A, Aoyama T, Ohno T, Maruyama R et al. A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. J Cardiovasc Pharmacol 2006; 48: 160-165.
30. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by Tlymphocytes in human abdominal aortic aneurysms. Circulation 1999; 99: 96-104.